Business Wire

Surgisphere Releases ‘Rapid COVID-19 Triage Tool’ Internationally

19.3.2020 17:01:00 EET | Business Wire | Press release

Share

As hospitals start to prepare for a surge in confirmed cases of COVID-19, a more pronounced focus will be placed on the appropriate utilization of healthcare resources. Without planning and organization, this surge can lead to delays in care and wasted resources, both of which hurt patients. In conjunction with public health experts, Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care (https://surgisphere.com/covid-19-triage-tool/).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005377/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Access a rapid triage tool for front line healthcare professionals to optimize the delivery of timely and effective healthcare to COVID-19 patients. (Graphic: Business Wire)

Surgisphere leveraged its real time global research network to develop this triage tool. Using its #1 ranked machine learning capabilities, Surgisphere identified the clinical signs and symptoms most predictive of poor outcomes. Using patient age, chronic medical conditions such as cardiovascular disease and diabetes, vital signs, and routine physical exam maneuvers, healthcare professionals on the front line can triage a COVID-19 patient in under a minute.

“This smartphone app will help thousands of vulnerable patients. We have already seen healthcare systems around the world struggling to cope with the extensive number of sick patients. Better triaging them to provide vital healthcare to those who need it the most is a top priority. Our data driven approach combined with advanced machine learning has created a solution that can positively impact healthcare delivery,” said Sapan Desai, MD, PhD, MBA, FACS. Dr. Desai is a vascular surgeon and President and Chief Executive Officer of the Surgisphere Corporation.

This triage tool has been prospectively validated and has a 95.5% overall accuracy. 100% of patients who require immediate attention are correctly triaged. This smartphone app can be accessed at https://www.Surgisphere.com. Surgisphere has also created a COVID-19 mortality risk calculator and diagnosis decision support tool, all freely and immediately available to healthcare professionals around the world.

Surgisphere is currently leveraging its coordinated efforts with global health agencies and its own global network of over 1,200 healthcare organizations to facilitate rapid, world-wide deployment of this life-saving tool. The methodology and results associated with this triage tool have been submitted for peer review and publication in a scientific journal.

Surgisphere is a physician-led company dedicated to making the world a better place, a mission that has motivated its growth and progress since its inception in 2008. An ISO 27001:2013 certified corporation in Chicago, Surgisphere has developed leading solutions in healthcare delivery for patients with kidney disease, cardiovascular disease, lymphedema, and other major diseases.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sapan Desai
sapan.desai@surgisphere.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB to Host 2026 Digital Investor Day10.6.2026 15:30:00 EEST | Press release

SLB (NYSE: SLB) will host an Investor Day on Wednesday, June 17, 2026, in New York, where leadership will outline their vision for SLB’s Digital business as digital technologies and AI continue to reshape the energy industry. The presentation will highlight SLB’s integrated digital strategy and portfolio, scalable growth opportunities powered by AI, and financial profile and outlook. Olivier Le Peuch, chief executive officer, SLB, will present at 9:00 a.m. U.S. Eastern Time (ET), and will discuss SLB’s digital strategy and business outlook. Stephane Biguet, chief financial officer, SLB, will present at approximately 11:00 a.m. ET, and will discuss the financial profile of SLB’s Digital business, the market opportunity and SLB’s 2030 digital ambitions. Mr. Le Peuch and Mr. Biguet will be joined by divisional leadership, who will provide further insight into Digital’s competitive differentiation supported by its mission-critical platform, driving transformation for customers. A live webc

Macrobond Launches AI Data Feed with MCP and Skill, Bringing Governed Macroeconomic Intelligence to Enterprise AI Workflows10.6.2026 15:00:00 EEST | Press release

Macrobond today announced the general availability of the Macrobond AI Data Feed Service, a purpose-built product, enabling financial institutions to integrate governed macroeconomic intelligence directly into AI-powered research, investment, and strategy workflows. Available now with MCP, Skill and API delivery components, the AI Data Feed helps organizations accelerate macroeconomic research and insight generation and reduce reliance on fragmented or ungoverned data sources. By delivering reliable, licensed, economic data integrated directly within AI chat interfaces and coding environments, the AI Data Feed Service provides a trusted foundation for enterprise AI initiatives. As generative AI becomes embedded in research, investment, and strategy workflows, face a foundational challenge: most AI systems operate on ungoverned data producing outputs that are difficult to trust, reproduce, or audit. The Macrobond AI Data Feed Service directly addresses this gap by connecting customer’s

Wolters Kluwer expands its Libra AI workspace with authoritative Swiss legal content from leading publisher Stämpfli10.6.2026 15:00:00 EEST | Press release

Wolters Kluwer Legal & Regulatory today announced the expansion of Libra by Wolters Kluwer, its AI-powered legal workspace, to include professional legal content from Stämpfli Publishers, one of Switzerland’s most respected legal publishers. As a result, Swiss legal professionals using Libra by Wolters Kluwer gain direct access to the legal literature that shapes their daily work – fully integrated into a single AI-supported workflow. The content offering includes commentaries, practitioner guides, yearbooks and selected journals from Stämpfli Publishers – including the renowned “Berner Kommentar”, and the company’s succinct commentaries and legal textbooks. In addition, primary sources of Swiss law at both federal and cantonal level are integrated into the workspace. The offering will be continuously expanded over time, with additional titles gradually integrated into the working environment. Libra by Wolters Kluwer provides a fully integrated and secure working environment in which l

Parse Biosciences Launches the Next Generation of its Immune Profiling Kits10.6.2026 15:00:00 EEST | Press release

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale. Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-throughput immune studies. Both Evercode TCR and Evercode BCR are now built on the same v4 chemistry that powers the latest Evercode Wh

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 14:47:00 EEST | Press release

GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye